We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-12.58%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.2B
AUM Growth
+$58.8M
Cap. Flow
+$619M
Cap. Flow %
19.37%
Top 10 Hldgs %
58.78%
Holding
99
New
23
Increased
20
Reduced
15
Closed
12

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$158M
2
ZLAB icon
Zai Lab
ZLAB
+$107M
3
ARVN icon
Arvinas
ARVN
+$93.6M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$70.9M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$59.4M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$81.7M
2
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$77.3M
3
RCUS icon
Arcus Biosciences
RCUS
+$75.7M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$63.6M
5
ITOS
iTeos Therapeutics
ITOS
+$44.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Financials 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LENZ
51
LENZ Therapeutics
LENZ
$181M
$5.22M 0.16%
146,326
+47,912
+49% +$3M
NUVB.WS
52
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$5.07M 0.16%
963,333
– –
JYAC
53
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.92M 0.15%
500,000
– –
CCCC icon
54
C4 Therapeutics
CCCC
$405M
$4.85M 0.15%
200,000
– –
CNTA
55
DELISTED
Centessa Pharmaceuticals
CNTA
$4.08M 0.13%
454,545
-427,631
-48% -$3.9M
OBIO icon
56
Orchestra BioMed
OBIO
$239M
$3.96M 0.12%
400,000
– –
GRCL
57
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$3.63M 0.11%
+1,559,710
New +$5.32M
NRIX icon
58
Nurix Therapeutics
NRIX
$2.45B
$3.56M 0.11%
254,473
-55,067
-18% -$977K
SLDB icon
59
Solid Biosciences
SLDB
$836M
$3.08M 0.1%
171,007
-442,506
-72% -$7.81M
KRON
60
DELISTED
Kronos Bio
KRON
$2.36M 0.07%
326,780
-60,577
-16% -$517K
ITOS
61
DELISTED
iTeos Therapeutics
ITOS
$2.34M 0.07%
72,821
-1,230,336
-94% -$44.7M
VERV
62
DELISTED
Verve Therapeutics
VERV
$2.25M 0.07%
98,593
-1,407
-1% -$40.2K
MLTX icon
63
MoonLake Immunotherapeutics
MLTX
$1.62B
$2.22M 0.07%
200,000
– –
DYN icon
64
Dyne Therapeutics
DYN
$4.8B
$2.07M 0.06%
215,000
– –
BLSA
65
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$1.97M 0.06%
200,000
– –
KNTE
66
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$1.97M 0.06%
175,000
– –
FVAM
67
DELISTED
5:01 Acquisition Corp
FVAM
$1.97M 0.06%
200,000
– –
EUCR
68
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$1.97M 0.06%
200,000
– –
ACIU icon
69
AC Immune
ACIU
$241M
$1.94M 0.06%
485,005
-264,580
-35% -$1.15M
ARYD
70
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.47M 0.05%
150,000
– –
PRDS
71
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$1.39M 0.04%
200,000
-1,397,139
-87% -$13.7M
ADVM
72
DELISTED
Adverum Biotechnologies
ADVM
$1.37M 0.04%
104,670
– –
MRSN
73
DELISTED
Mersana Therapeutics
MRSN
$1.3M 0.04%
+13,063
New +$1.53M
SPRY icon
74
ARS Pharmaceuticals
SPRY
$559M
$1.16M 0.04%
329,537
-730,473
-69% -$3.18M
BCEL
75
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$1.14M 0.04%
+358,780
New +$870K
1 2
3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q1 2022 Portfolio in Review

As of Q1 2022, EcoR1 Capital held 99 positions worth $3.2B, up 1.9% from $3.14B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

EcoR1 Capital deployed $619M of net new capital in Q1 2022, opening 23 new positions and adding to 20 existing holdings. Its largest new stake was Sarepta Therapeutics: 2,069,634 shares worth $162M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $75.7M trimmed.

  • EcoR1 Capital's largest Q1 2022 buy was Sarepta Therapeutics: 2,069,634 shares worth $162M.
  • EcoR1 Capital added most to Arvinas in Q1 2022, an estimated $93.6M increase.
  • EcoR1 Capital's biggest Q1 2022 reduction was Arcus Biosciences, cutting an estimated $75.7M.
  • EcoR1 Capital fully exited CRISPR Therapeutics in Q1 2022, selling an estimated $81.7M.
  • EcoR1 Capital's ten largest holdings make up 59% of its $3.2B portfolio in Q1 2022.
  • EcoR1 Capital opened 23 new positions and closed 12 in Q1 2022.
  • EcoR1 Capital's portfolio value rose 1.9% quarter-over-quarter to $3.2B.

Based on EcoR1 Capital's 13F filing for Q1 2022, filed 16 May 2022.